Cns Selling And Marketing Expenses vs Operating Income Analysis

CNSP Stock

USD 0.12 0.01 7.69%

Cns Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cns Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cns Pharmaceuticals is a good investment. Please check the relationship between Cns Pharmaceuticals Selling And Marketing Expenses and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.

Selling And Marketing Expenses vs Operating Income

Selling And Marketing Expenses vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cns Pharmaceuticals Selling And Marketing Expenses account and Operating Income. At this time, the significance of the direction appears to have strong relationship.

The correlation between Cns Pharmaceuticals' Selling And Marketing Expenses and Operating Income is 0.66. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Operating Income in the same time period over historical financial statements of Cns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cns Pharmaceuticals' Selling And Marketing Expenses and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Cns Pharmaceuticals are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Selling And Marketing Expenses i.e., Cns Pharmaceuticals' Selling And Marketing Expenses and Operating Income go up and down completely randomly.

Correlation Coefficient

0.66

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Selling And Marketing Expenses

Operating Income

Operating Income is the amount of profit realized from Cns Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cns Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Cns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.As of 11/26/2024, Issuance Of Capital Stock is likely to grow to about 9.7 M, while Selling General Administrative is likely to drop slightly above 3.6 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	14.0M	15.3M	18.9M	9.9M
Research Development	9.3M	9.3M	14.1M	14.8M

Total Operating Expenses Research Development

Cns Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue	Other Assets
Total Assets		0.81	-0.05	0.32	0.91	0.86	-0.98	-0.39	0.23	0.99	0.99	0.74	0.15	0.77	0.67	0.74	0.64	0.32	0.92	0.81	1.0	0.9	0.81	0.43	-0.8	0.42
Short Long Term Debt Total	0.81		0.35	0.59	0.6	0.87	-0.76	-0.66	0.53	0.77	0.77	0.82	-0.36	0.55	0.86	0.69	0.77	0.59	0.61	1.0	0.81	0.58	1.0	0.41	-0.92	0.38
Other Current Liab	-0.05	0.35		0.88	-0.43	0.38	0.12	-0.85	0.92	-0.11	-0.11	0.51	-0.6	-0.14	0.68	0.24	0.63	0.88	-0.42	0.35	-0.05	-0.45	0.35	-0.21	-0.46	-0.24
Total Current Liabilities	0.32	0.59	0.88		-0.1	0.58	-0.21	-0.98	0.99	0.23	0.23	0.76	-0.31	0.34	0.87	0.66	0.87	1.0	-0.08	0.59	0.31	-0.13	0.59	-0.19	-0.69	-0.09
Total Stockholder Equity	0.91	0.6	-0.43	-0.1		0.65	-0.94	0.02	-0.18	0.94	0.94	0.44	0.29	0.65	0.33	0.49	0.29	-0.1	1.0	0.6	0.91	1.0	0.6	0.54	-0.54	0.48
Net Tangible Assets	0.86	0.87	0.38	0.58	0.65		-0.83	-0.66	0.54	0.84	0.84	0.88	-0.25	0.45	0.87	0.61	0.8	0.58	0.66	0.87	0.86	0.64	0.87	0.44	-0.93	0.34
Net Debt	-0.98	-0.76	0.12	-0.21	-0.94	-0.83		0.28	-0.13	-1.0	-1.0	-0.65	-0.13	-0.7	-0.58	-0.65	-0.54	-0.21	-0.94	-0.76	-0.99	-0.94	-0.76	-0.41	0.73	-0.32
Retained Earnings	-0.39	-0.66	-0.85	-0.98	0.02	-0.66	0.28		-0.98	-0.29	-0.29	-0.83	0.32	-0.37	-0.92	-0.69	-0.92	-0.98	0.0	-0.66	-0.37	0.05	-0.66	0.07	0.79	-0.06
Accounts Payable	0.23	0.53	0.92	0.99	-0.18	0.54	-0.13	-0.98		0.14	0.14	0.72	-0.34	0.24	0.85	0.59	0.84	0.99	-0.17	0.53	0.22	-0.21	0.53	-0.18	-0.68	-0.07
Cash	0.99	0.77	-0.11	0.23	0.94	0.84	-1.0	-0.29	0.14		1.0	0.66	0.13	0.7	0.59	0.66	0.55	0.23	0.94	0.77	0.99	0.93	0.77	0.41	-0.74	0.33
Cash And Short Term Investments	0.99	0.77	-0.11	0.23	0.94	0.84	-1.0	-0.29	0.14	1.0		0.66	0.13	0.7	0.59	0.66	0.55	0.23	0.94	0.77	0.99	0.93	0.77	0.41	-0.74	0.33
Common Stock Total Equity	0.74	0.82	0.51	0.76	0.44	0.88	-0.65	-0.83	0.72	0.66	0.66		-0.18	0.57	0.93	0.74	0.97	0.76	0.45	0.82	0.72	0.41	0.82	0.26	-0.91	0.36
Common Stock Shares Outstanding	0.15	-0.36	-0.6	-0.31	0.29	-0.25	-0.13	0.32	-0.34	0.13	0.13	-0.18		0.54	-0.31	0.3	-0.17	-0.31	0.28	-0.36	0.14	0.28	-0.36	-0.16	0.24	0.12
Non Current Liabilities Total	0.77	0.55	-0.14	0.34	0.65	0.45	-0.7	-0.37	0.24	0.7	0.7	0.57	0.54		0.48	0.91	0.58	0.34	0.66	0.55	0.76	0.63	0.55	0.02	-0.54	0.29
Capital Surpluse	0.67	0.86	0.68	0.87	0.33	0.87	-0.58	-0.92	0.85	0.59	0.59	0.93	-0.31	0.48		0.74	0.94	0.87	0.34	0.86	0.66	0.3	0.86	0.25	-0.94	0.3
Other Current Assets	0.74	0.69	0.24	0.66	0.49	0.61	-0.65	-0.69	0.59	0.66	0.66	0.74	0.3	0.91	0.74		0.8	0.66	0.51	0.69	0.73	0.46	0.69	-0.02	-0.75	0.25
Other Stockholder Equity	0.64	0.77	0.63	0.87	0.29	0.8	-0.54	-0.92	0.84	0.55	0.55	0.97	-0.17	0.58	0.94	0.8		0.87	0.3	0.77	0.63	0.26	0.77	0.05	-0.89	0.22
Total Liab	0.32	0.59	0.88	1.0	-0.1	0.58	-0.21	-0.98	0.99	0.23	0.23	0.76	-0.31	0.34	0.87	0.66	0.87		-0.08	0.59	0.31	-0.13	0.59	-0.19	-0.69	-0.09
Net Invested Capital	0.92	0.61	-0.42	-0.08	1.0	0.66	-0.94	0.0	-0.17	0.94	0.94	0.45	0.28	0.66	0.34	0.51	0.3	-0.08		0.61	0.92	1.0	0.61	0.54	-0.55	0.48
Short Long Term Debt	0.81	1.0	0.35	0.59	0.6	0.87	-0.76	-0.66	0.53	0.77	0.77	0.82	-0.36	0.55	0.86	0.69	0.77	0.59	0.61		0.81	0.58	1.0	0.41	-0.92	0.38
Total Current Assets	1.0	0.81	-0.05	0.31	0.91	0.86	-0.99	-0.37	0.22	0.99	0.99	0.72	0.14	0.76	0.66	0.73	0.63	0.31	0.92	0.81		0.91	0.81	0.41	-0.79	0.38
Net Working Capital	0.9	0.58	-0.45	-0.13	1.0	0.64	-0.94	0.05	-0.21	0.93	0.93	0.41	0.28	0.63	0.3	0.46	0.26	-0.13	1.0	0.58	0.91		0.58	0.52	-0.52	0.43
Short Term Debt	0.81	1.0	0.35	0.59	0.6	0.87	-0.76	-0.66	0.53	0.77	0.77	0.82	-0.36	0.55	0.86	0.69	0.77	0.59	0.61	1.0	0.81	0.58		0.41	-0.92	0.38
Common Stock	0.43	0.41	-0.21	-0.19	0.54	0.44	-0.41	0.07	-0.18	0.41	0.41	0.26	-0.16	0.02	0.25	-0.02	0.05	-0.19	0.54	0.41	0.41	0.52	0.41		-0.35	0.84
Current Deferred Revenue	-0.8	-0.92	-0.46	-0.69	-0.54	-0.93	0.73	0.79	-0.68	-0.74	-0.74	-0.91	0.24	-0.54	-0.94	-0.75	-0.89	-0.69	-0.55	-0.92	-0.79	-0.52	-0.92	-0.35		-0.4
Other Assets	0.42	0.38	-0.24	-0.09	0.48	0.34	-0.32	-0.06	-0.07	0.33	0.33	0.36	0.12	0.29	0.3	0.25	0.22	-0.09	0.48	0.38	0.38	0.43	0.38	0.84	-0.4

Click cells to compare fundamentals

Cns Pharmaceuticals Account Relationship Matchups

Cns Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.9M	15.9M	8.8M	13.1M	1.7M	1.6M
Other Current Liab	21.5K	519.8K	224.9K	828.4K	5.8M	6.1M
Total Current Liabilities	311.0K	1.9M	2.1M	4.9M	6.1M	6.4M
Total Stockholder Equity	7.6M	13.9M	6.6M	8.1M	(4.4M)	(4.2M)
Net Tangible Assets	(549.3K)	7.6M	13.6M	6.6M	7.6M	6.0M
Net Debt	(7.2M)	(13.6M)	(4.6M)	(9.6M)	(247.9K)	(260.3K)
Retained Earnings	(11.5M)	(20.9M)	(35.0M)	(50.7M)	(69.6M)	(66.1M)
Accounts Payable	289.5K	946.3K	2.0M	3.7M	5.8M	6.1M
Cash	7.2M	14.0M	5.0M	10.1M	548.7K	521.3K
Non Current Assets Total	18.2K	357.6K	1.3M	488.5K	109.7K	104.2K
Cash And Short Term Investments	7.2M	14.0M	5.0M	10.1M	548.7K	521.3K
Common Stock Shares Outstanding	548.3K	11.1M	17.6M	27.2M	75.3K	71.6K
Liabilities And Stockholders Equity	7.9M	15.9M	8.8M	13.1M	1.7M	1.6M
Non Current Liabilities Total	445.8K	289.5K	1.4M	1.9M	4.1M	0.0
Other Current Assets	652.6K	1.5M	2.5M	5.0M	1.0M	1.7M
Other Stockholder Equity	19.1M	34.9M	41.6M	58.8M	65.1M	35.6M
Total Liab	311.0K	1.9M	2.1M	4.9M	6.1M	6.4M
Net Invested Capital	7.6M	14.4M	7.0M	8.5M	(4.1M)	(3.9M)
Total Current Assets	7.9M	15.5M	7.5M	12.6M	1.6M	1.5M
Net Working Capital	7.6M	13.6M	5.3M	7.6M	(4.5M)	(4.3M)
Common Stock	16.5K	23.9K	27.9K	1.6K	6.2K	11.3K
Capital Stock	16.5K	23.9K	27.9K	1.6K	6.2K	11.8K

Pair Trading with Cns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cns Stock

0.75	VALN	Valneva SE ADR	Pair Corr
0.71	VCNX	Vaccinex	Pair Corr

Moving against Cns Stock

0.72	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.7	GILD	Gilead Sciences	Pair Corr
0.68	EWTX	Edgewise Therapeutics	Pair Corr
0.6	KZR	Kezar Life Sciences	Pair Corr
0.59	VRDN	Viridian Therapeutics	Pair Corr

The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.

The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC